Estratificación de la población mayor de 65 años en grupos de riesgo clínico: características y valoración enfermera

Lozano-Vidal, Ruth; López-Pisa, Rosa María; Boyero-Granados, Ana; Recio-Ramos, Sandra; Padín-Minaya, Cristina; Garzón-Quiñones, Marina; Rodríguez-Latre, Luisa M.

doi:10.1016/j.enfcli.2014.06.001

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comorbidities were analyzed using the Clinical Risk Group (CRG) [36]. The CRG are a population classification system that uses inpatient and ambulatory diagnosis and procedure codes, pharmaceutical data and functional health status to assign each individual to a single, severity-adjusted group.…”

Section: Comorbiditiesmentioning

confidence: 99%

“…The CRG are a population classification system that uses inpatient and ambulatory diagnosis and procedure codes, pharmaceutical data and functional health status to assign each individual to a single, severity-adjusted group. These groups report the individual health status and illness severity level, contemplating whether the disease is acute or chronic and the number of organs or systems affected [22,36,37]. Those presenting a high comorbidity index, which corresponded to chronic diseases in 2 or more affected organs and a high severity level (≥6/05), were selected for closer analysis.…”

Section: Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study

Amoros-Reboredo

Soy

Hernández

et al. 2020

IJERPH

View full text Add to dashboard Cite

Aim: Older patients with chronic hepatitis C infection starting direct-acting antivirals (DAAs) are frequently prescribed multiple medications that may be categorized as inappropriate. Anticholinergic burden has been shown to be a predictor of adverse health and functional outcomes. Different scales are available to calculate anticholinergic burden. The aim of this study was to determine the prevalence of anticholinergic medication among older patients treated with DAAs and the risk factors associated using the Anticholinergic Cognitive Burden (ACB) scale, the Anticholinergic Risk Scale (ARS) and the Anticholinergic Drug Scale (ADS) and analyze the resulting safety consequences. Methods: Observational, retrospective cohort study of consecutive patients ≥65 years old receiving DAAs and taking concomitant medication. This study was conducted in accordance with the Strengthening the Reporting of observational studies in Epidemiology Statement. Results: 236 patients were included. The average age was 71.7 years, 73.3% cirrhotic, and 47% patients took ≥5 medicines. According to the ACB, ARS and ADS scales, 35.2% (n = 83), 10.6% (n = 25) and 34.3% (n = 81) of the patients were treated with anticholinergic medication. Two hundred-and-six (86%) patients presented any adverse events (AEs) during therapy. ARS scale showed a significant relationship between presence of anticholinergic medication and AEs. A large number of patients suffered anticholinergic events, with more events per patient in patients taking anticholinergic drugs. Conclusions: Older hepatitis C chronic patients are exposed to potentially inappropriate polypharmacy and anticholinergic risk, according to the ACB, ARS and ADS scales. The three scales showed different results. Only the ARS scale was associated with AEs, but the rate of anticholinergic effects per patient was significantly higher in patients with anticholinergic drugs, regardless of the scale used. Consider quality of pharmacotherapy when starting DAA with a multidisciplinary approach could improve health outcomes.

show abstract

Section: Comorbiditiesmentioning

confidence: 99%

Section: Comorbiditiesmentioning

confidence: 99%